Bicycle Therapeutics Plc ADR
Bicycle Therapeutics Plc ADR (BCYC) Historical Volatility
BCYC's 30 day historical volatility is 50.98%, in the 49th percentile of readings over the past year. This is an average percentile, meaning Bicycle Therapeutics Plc ADR shares have moved roughly in line with their typical range. BCYC's 30 day implied volatility sits at 360.19%, with an IV Rank of 86.11%, leaving IV 309.21 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 17, 2026.
Read more
Tracking BCYC historical volatility helps you see how much Bicycle Therapeutics Plc ADR's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, BCYC's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor BCYC 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. BCYC's 30 day historical volatility, or BCYC HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing BCYC's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase.
Historical Volatility
Historical movement is near its typical level for the past year. Neither unusually calm nor unusually active.
As of Nov 17, 2026
As of Nov 17, 2026
As of Nov 17, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →